Author + information
- 1North Shore University Hospital- Northwell Health, Manhasset, New York, United States
- 2Cardiovascular Research Foundation, New York, New York, United States
- 3Northshore University Hospital, Manhasset, New York, United States
- 4Hofstra Northwell School of Medicine, New York, Manhasset, New York, United States
Transcatheter Mitral Valve Repair (TMR) for treatment of severe mitral regurgitation has been shown to be an effective treatment for. Mitraclip is approved for degenerative disease treatment in US. However, the impact of gender on in-hospital outcomes has not been studied on a large scale. The aim of this study was to examine gender differences in in-hospital outcomes, length of stay and cost after TMR.
Data from the National Inpatient Sample (NIS) (2012 through 2014) using the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) procedure code 35.97 for TMR was analyzed for this study. SAS 9.4 (SAS institute, Cary, NC) was used for univariate and multivariate analysis. Multivariate Logistic regression model was created. Age and all comorbidities were included in the model. Race was not included because of missing data.
A total of 521 patients were identified that were treated with TMR. Females accounted for 42.03% of the population in our study. The primary outcome, in-hospital mortality was not higher in females [Odds Ratio 1.62 (95% Confidence Interval, 0.50-5.28)]. No difference in any secondary outcomes were noted after performing multivariate logistic regression analysis. No Difference in length of stay or median hospitalization cost was noted as well.
Analysis of this large database of patients undergoing TMR suggests that in-hospital mortality, morbidity, length of stay or cost are comparable in both gender. Our study suggests that further randomized data is needed to fully assess gender disparities in patients being treated with TMR.
STRUCTURAL: Valvular Disease: Mitral